HBV Disease Progression
AASLD 2016: Is Improved Treatment Reducing Liver Cancer Among People with Hepatitis B?
- Details
- Category: HBV Disease Progression
- Published on Wednesday, 15 February 2017 00:00
- Written by Liz Highleyman
The incidence of hepatocellular carcinoma (HCC) appears to be decreasing and mortality improving among chronic hepatitis B patients treated with suppressive antiviral therapy, according to studies presented at the recent 2016 AASLD Liver Meeting in Boston. However, liver cancer remains a major indication for liver transplants and has a negative effect on survival of people with hepatitis B.
AASLD 2016: Nivolumab Shows Good Safety and Promising Response Rates in Liver Cancer Study
- Details
- Category: Liver Cancer/HCC
- Published on Thursday, 15 December 2016 00:00
- Written by Liz Highleyman
Nivolumab (Opdivo), an antibody that blocks the PD-1 receptor and restores T-cell anti-tumor activity, appeared safe and was associated with disease control and stabilization in a Phase 1/2 study of patients with hepatocellular carcinoma, according to late-breaking results from the CheckMate 040 study presented at the AASLD Liver Meeting last month in Boston.
Cancer Is Falling Overall But Liver Cancer Is Rising, Largely Due to Hepatitis B and C
- Details
- Category: Liver Cancer/HCC
- Published on Tuesday, 15 March 2016 00:00
- Written by Liz Highleyman
Overall cancer rates have declined significantly in the U.S. over the past decade thanks to better screening and prevention, with the notable exception of liver cancer, according to a new Annual Report to the Nation on the Status of Cancer. A majority of liver cancer is caused by hepatitis B virus (HBV), which is preventable with a vaccine, or hepatitis C virus (HCV), which can now be cured in most cases.
Blood Test Could Help Predict Which Hepatitis B Patients Will Develop Liver Cancer
- Details
- Category: Liver Cancer/HCC
- Published on Thursday, 09 June 2016 00:00
- Written by Thomas Jefferson University
A blood test that measures a set of circulating microRNAs (miRNAs) may help identify who will develop hepatitis B virus-related hepatocellular carcinoma (HCC), a type of primary liver cancer, according to research published in the May 24 online edition of OncoTarget.
Hepatitis B Vaccine, Hepatitis C Treatment Could Prevent Most Liver Cancer
- Details
- Category: Liver Cancer/HCC
- Published on Thursday, 04 February 2016 00:00
- Written by World Hepatitis Alliance
Widespread vaccination against hepatitis B virus (HBV) and prompt treatment of chronic hepatitis C virus (HCV) -- which together are the most common cause of hepatocellular carcinoma -- could prevent an estimated 80% of liver cancer deaths, according to the World Hepatitis Alliance in an announcement commemorating World Cancer Day.
More Articles...
- AASLD 2015: Coffee Linked to Reduced Liver Fibrosis in People with HBV, HCV, and NAFLD
- Antiviral Treatment for Hepatitis B Improves Liver Function after Decompensation
- ASCO 2015: PD-1 Checkpoint Inhibitor Nivolumab Shows Promise against Liver Cancer
- EASL 2015: HBV Patients on Long-term Entecavir or Tenofovir Have Low Mortality, HCC Still a Risk